INDEMNITY AGREEMENTIndemnity Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnity Agreement, dated as of , is made by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and , a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).
VICE PRESIDENT SEVERANCE AGREEMENTSeverance Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This Vice President Severance Agreement (the “Agreement”) is entered into as of July 10, 2015 (the “Effective Date”) by and between Scott W. Rowlinson, Ph.D. (the “Employee”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”).
PATENT LICENSE AGREEMENT AGREEMENT NO. PM1401601Patent License Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This Patent License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, ‘Party”).
Master Services AgreementMaster Services Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • North Carolina
This Master Services Agreement (this “Agreement”) dated December 24, 2013 (the “Effective Date”), between Aeglea Development Company, Inc., having a place of business at 815-A Brazos St. #101, Austin, TX 78701 (“Client”) and KBI Biopharma, Inc., having a place of business at 1101 Hamlin Road, Durham, North Carolina 27704 (“KBI Biopharma”) (Client and KBI Biopharma, each a “Party”, and collectively, the “Parties”).
SPONSORED RESEARCH AGREEMENT NO. UTA13-001113Sponsored Research Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”). Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate.
CEO SERVERANCE AGREEMENTCeo Severance Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This CEO Severance Agreement (the “Agreement”) is entered into as of July 7, 2015 (the “Effective Date”) by and between David G. Lowe, Ph.D. (the “Executive”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), is made and entered into as of July 7, 2015 (the “Effective Date”), by and between Aeglea Development Company, Inc., a Delaware corporation (the “Company”) and David G. Lowe (“Executive”).
